Edition:
United Kingdom

Biotechnology & Medical Research

Bridgebio, Eidos Present Data From Phase 2 Open Label Extension Suggesting Long-Term Tolerability Of AG10

Nov 16 (Reuters) - Bridgebio Pharma Inc ::BRIDGEBIO, EIDOS PRESENT DATA FROM PHASE 2 OPEN LABEL EXTENSION SUGGESTING LONG-TERM TOLERABILITY OF AG10.AG10 WAS WELL TOLERATED WITH MEDIAN 65 WEEKS FOLLOW-UP SINCE PHASE 2 INITIATION.NEAR-COMPLETE STABILIZATION OF TTR MAINTAINED IN PARTICIPANTS THROUGHOUT...

Saturday, 16 Nov 2019

Caladrius Biosciences Reports Positive Results For CLBS16 From Escape-CMD Trial

Nov 16 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS POSITIVE RESULTS FOR CLBS16 FROM ESCAPE-CMD TRIAL AT AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2019.TRIAL INVESTIGATORS OBSERVED PATIENTS HAD HIGH (P=0.0087) INCREASE IN CORONARY FLOW RESERVE AFTER SINGLE INTRACORONARY...

Saturday, 16 Nov 2019

Kiniksa Says Presents Rilonacept Final Phase 2 Clinical Data At The American Heart Association Scientific Sessions 2019

Nov 16 (Reuters) - Kiniksa Pharmaceuticals Ltd ::KINIKSA PRESENTS RILONACEPT FINAL PHASE 2 CLINICAL DATA AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2019.PIVOTAL PHASE 3 TRIAL OF RILONACEPT IN RECURRENT PERICARDITIS (RHAPSODY) ENROLLING; DATA EXPECTED IN 2H 2020.

Saturday, 16 Nov 2019

Aprea Therapeutics Inc Qtrly Net Loss Per Share, Basic And Diluted $5.29

Nov 14 (Reuters) - Aprea Therapeutics Inc ::APREA THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.APREA THERAPEUTICS INC - QTRLY NET LOSS PER SHARE , BASIC AND DILUTED $5.29.

Thursday, 14 Nov 2019

Expansion & New Markets

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.